PCM
INFI

Prelude Capital Management’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Prelude Capital Management’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-2,000
Closed -$24K – 2235
2014
Q1 		$24K Buy
+2,000
New +$26.8K ﹤0.01% 1635

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Prelude Capital Management's INFI Position: Q4 2018 in Review

Prelude Capital Management sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q4 2018, closing a stake of 157,247 shares — an estimated $426K sold.

Prelude Capital Management first reported a position in INFI in Q2 2013 and held it in 15 quarters. The position peaked at $426K in Q3 2018. 64 funds tracked by Wall St. Rank hold INFI as of Q4 2018.

  • Prelude Capital Management reported no remaining Infinity Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Prelude Capital Management sold 157,247 Infinity Pharmaceuticals, Inc. shares in Q4 2018, an estimated $426K.
  • Prelude Capital Management first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 15 quarters.
  • Prelude Capital Management's Infinity Pharmaceuticals, Inc. position peaked at $426K in Q3 2018.
  • 64 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q4 2018.

Based on Prelude Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.